Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates

Efforts to develop an HIV-1 vaccine include those focusing on conserved structural elements as the target of broadly neutralizing monoclonal antibodies. MAb D5 binds to a highly conserved hydrophobic pocket on the gp41 N-heptad repeat (NHR) coiled coil and neutralizes through prevention of viral fus...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 121; no. 22; p. e2317230121
Main Authors Wu, Chengwei, Raheem, Izzat T., Nahas, Debbie D., Citron, Michael, Kim, Peter S., Montefiori, David C., Ottinger, Elizabeth A., Hepler, Robert W., Hrin, Renee, Patel, Sangita B., Soisson, Stephen M., Joyce, Joseph G.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 28.05.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Efforts to develop an HIV-1 vaccine include those focusing on conserved structural elements as the target of broadly neutralizing monoclonal antibodies. MAb D5 binds to a highly conserved hydrophobic pocket on the gp41 N-heptad repeat (NHR) coiled coil and neutralizes through prevention of viral fusion and entry. Assessment of 17-mer and 36-mer NHR peptides presenting the D5 epitope in rodent immunogenicity studies showed that the longer peptide elicited higher titers of neutralizing antibodies, suggesting that neutralizing epitopes outside of the D5 pocket may exist. Although the magnitude and breadth of neutralization elicited by NHR-targeting antigens are lower than that observed for antibodies directed to other epitopes on the envelope glycoprotein complex, it has been shown that NHR-directed antibodies are potentiated in TZM-bl cells containing the FcγRI receptor. Herein, we report the design and evaluation of covalently stabilized trimeric 51-mer peptides encompassing the complete gp41 NHR. We demonstrate that these peptide trimers function as effective antiviral entry inhibitors and retain the ability to present the D5 epitope. We further demonstrate in rodent and nonhuman primate immunization studies that our 51-mer constructs elicit a broader repertoire of neutralizing antibody and improved cross-clade neutralization of primary HIV-1 isolates relative to 17-mer and 36-mer NHR peptides in A3R5 and FcγR1-enhanced TZM-bl assays. These results demonstrate that sensitive neutralization assays can be used for structural enhancement of moderately potent neutralizing epitopes. Finally, we present expanded trimeric peptide designs which include unique low-molecular-weight scaffolds that provide versatility in our immunogen presentation strategy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
5Present Address: Sola Salons, Horsham, PA 19044.
4Present address: Cell Engineering and Analytical Sciences, The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA 19477.
6Present Address: Odyssey Therapeutics, Boston, MA 02210.
Edited by William DeGrado, University of California, San Francisco, CA; received November 13, 2023; accepted March 29, 2024
2Present address: Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305.
3Present address: Division of Preclinical Innovation, Therapeutic Development Branch, National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20892.
ISSN:0027-8424
1091-6490
1091-6490
DOI:10.1073/pnas.2317230121